» Articles » PMID: 24879835

Incidence of Lactic Acidosis in Patients with Type 2 Diabetes with and Without Renal Impairment Treated with Metformin: a Retrospective Cohort Study

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2014 Jun 1
PMID 24879835
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether the use of metformin in type 2 diabetic patients with various kidney functions is associated with an increased risk of lactic acidosis (LA).

Research Design And Methods: This study was a retrospective analysis of U.K. patient records from the Clinical Practice Research Datalink database from 1 January 2007 to 31 December 2012. Inclusion criteria were 1) diagnosis of type 2 diabetes before 1 January 2007, 2) treatment with metformin, and 3) at least one assessment of renal function between 2007 and 2012. Renal function was assessed by glomerular filtration rate and categorized as normal (N), mildly reduced (Mi), moderately reduced (Mo), or severely reduced (Se) function. The outcome of the study was LA.

Results: A total of 77,601 patients treated with metformin for type 2 diabetes were identified. There were 35 LA events (10.37 [95% CI 7.22-14.42] per 100,000 patient-years) of which none were fatal and 23 were linked to a comorbidity. No significant difference in the incidence of LA was observed across N, Mi, Mo and Se renal function groups (7.6 [0.9-27.5], 4.6 [2.00-9.15], 17 [10.89-25.79], and 39 [4.72-140.89] cases per 100,000 patient-years, respectively).

Conclusions: The overall LA incidence rate for patients on metformin in this study was within the range of rates reported in the literature for patients with type 2 diabetes, and no significant difference was observed among patients with N, Mi, Mo, and Se function.

Citing Articles

Metformin-associated lactic acidosis: A mini review of pathophysiology, diagnosis and management in critically ill patients.

See K World J Diabetes. 2024; 15(6):1178-1186.

PMID: 38983827 PMC: 11229964. DOI: 10.4239/wjd.v15.i6.1178.


From liver to hormones: The endocrine consequences of cirrhosis.

Quiroz-Aldave J, Gamarra-Osorio E, Durand-Vasquez M, Rafael-Robles L, Gonzales-Yovera J, Quispe-Flores M World J Gastroenterol. 2024; 30(9):1073-1095.

PMID: 38577191 PMC: 10989500. DOI: 10.3748/wjg.v30.i9.1073.


Frequency and predictors of inappropriate medication dosages for cardiovascular disease prevention in chronic kidney disease patients: A retrospective cross-sectional study in a Malaysian primary care clinic.

Jamaluddin J, Mohamed-Yassin M, Jamil S, Mohamed Kamel M, Yusof M Heliyon. 2023; 9(4):e14998.

PMID: 37025791 PMC: 10070146. DOI: 10.1016/j.heliyon.2023.e14998.


Construction and dual internal validation of a short-term prognostic scoring tool for sepsis.

Li Y, He X, Li Z, Li D, Yuan X, Yang J Heliyon. 2023; 9(4):e14941.

PMID: 37025776 PMC: 10070133. DOI: 10.1016/j.heliyon.2023.e14941.


Metformin's Role in Hyperlactatemia and Lactic Acidosis in ICU Patients: A Systematic Review.

Mueller L, Moser M, Prazak J, Fuster D, Schefold J, Zuercher P Pharmacology. 2023; 108(3):213-223.

PMID: 36652938 PMC: 10233707. DOI: 10.1159/000528252.